
Diffusion Pharmaceuticals Inc
Prices are adjusted according to historical splits.

Vitals
- Today's Low:
- $3.74
- Today's High:
- $3.81
- Open Price:
- $3.8
- 52W Low:
- $3.55
- 52W High:
- $8.74
- Prev. Close:
- $3.81
- Volume:
- 3480
Company Statistics
- Market Cap.:
- $7.77 million
- Book Value:
- 7.98
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -27.86%
- Return on Equity TTM:
- -64.64%
Company Profile
Diffusion Pharmaceuticals Inc had its IPO on 2016-01-04 under the ticker symbol DFFN.
The company operates in the Healthcare sector and Biotechnology industry. Diffusion Pharmaceuticals Inc has a staff strength of 13 employees.
Stock update
Shares of Diffusion Pharmaceuticals Inc opened at $3.8 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $3.74 - $3.81, and closed at $3.78.
This is a -0.92% slip from the previous day's closing price.
A total volume of 3,480 shares were traded at the close of the day’s session.
In the last one week, shares of Diffusion Pharmaceuticals Inc have slipped by -10.12%.
Diffusion Pharmaceuticals Inc's Key Ratios
Diffusion Pharmaceuticals Inc has a market cap of $7.77 million, indicating a price to book ratio of 0.5113 and a price to sales ratio of 0.
In the last 12-months Diffusion Pharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-15878764. The EBITDA ratio measures Diffusion Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Diffusion Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -27.86% with a return of equity of -64.64%.
In Q1, Diffusion Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Diffusion Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-7.25 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Diffusion Pharmaceuticals Inc’s profitability.
Diffusion Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 1.6498. Its price to sales ratio in the trailing 12-months stood at 0.
Diffusion Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $18.40 million
- Total Liabilities
- $2.13 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Diffusion Pharmaceuticals Inc ended 2023 with $18.40 million in total assets and $0 in total liabilities. Its intangible assets were valued at $18.40 million while shareholder equity stood at $16.28 million.
Diffusion Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $2.13 million in other current liabilities, 2040.00 in common stock, $-149688923.00 in retained earnings and $0 in goodwill. Its cash balance stood at $14.65 million and cash and short-term investments were $17.64 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Diffusion Pharmaceuticals Inc’s total current assets stands at $18.40 million while long-term investments were $0 and short-term investments were $2.99 million. Its net receivables were $0 compared to accounts payable of $971455.00 and inventory worth $0.
In 2023, Diffusion Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Diffusion Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $3.78
- 52-Week High
- $8.74
- 52-Week Low
- $3.55
- Analyst Target Price
- $24.75
Diffusion Pharmaceuticals Inc stock is currently trading at $3.78 per share. It touched a 52-week high of $8.74 and a 52-week low of $8.74. Analysts tracking the stock have a 12-month average target price of $24.75.
Its 50-day moving average was $4.14 and 200-day moving average was $5.44 The short ratio stood at 1.24 indicating a short percent outstanding of 0%.
Around 24.1% of the company’s stock are held by insiders while 931.8% are held by institutions.
Frequently Asked Questions About Diffusion Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body’s ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.